APA (7th ed.) Citation

Vokes, E. E., & Steins, M. (2018). Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Annals of oncology, 29(4), . https://doi.org/10.1093/annonc/mdy041

Chicago Style (17th ed.) Citation

Vokes, Everett E., and Martin Steins. "Nivolumab Versus Docetaxel in Previously Treated Advanced Non-small-cell Lung Cancer (CheckMate 017 and CheckMate 057): 3-year Update and Outcomes in Patients with Liver Metastases." Annals of Oncology 29, no. 4 (2018). https://doi.org/10.1093/annonc/mdy041.

MLA (9th ed.) Citation

Vokes, Everett E., and Martin Steins. "Nivolumab Versus Docetaxel in Previously Treated Advanced Non-small-cell Lung Cancer (CheckMate 017 and CheckMate 057): 3-year Update and Outcomes in Patients with Liver Metastases." Annals of Oncology, vol. 29, no. 4, 2018, https://doi.org/10.1093/annonc/mdy041.